Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 19/20 | 0.71 |
| ▸ | KDR | P35968 | 17/20 | 0.71 |
| ▸ | EPHB4 | P54760 | 14/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651823 | 0.94 | EPHA2 (0.66) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL5647952 | 0.88 | EPHA2 (0.58) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL907202 | 0.86 | EPHA2 (0.95) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL5654477 | 0.86 | KDR (0.61) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL5652556 | 0.84 | EGFR (0.69) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL906797 | 0.84 | EPHA2 (1.00) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL5650446 | 0.82 | KDR (0.65) | EPHA2KDRERBB2EGFR | |
| SCHEMBL5652855 | 0.81 | EGFR (0.55) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL5648641 | 0.80 | KDR (0.53) | EPHA2KDREPHB4ERBB2EGFR | |
| SCHEMBL4359307 | 0.80 | EPHA2 (0.85) | EPHA2KDREPHB4ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | EPHA2 814/4885KDR 1/4885EPHB4 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.